ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,118.71
0.53%
US Tech 100
21,272.40
0.06%
다우존스 지수
44,565.07
0.92%
Bitcoin
103,900.39
-0.06%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Inozyme Pharma Inc (INZY) 시세

Inozyme Pharma Inc

Inozyme Pharma Inc (INZY)

NASDAQ
1.32
0.02
(1.54%)
마감 24 1월 6:00AM
15분 지연
1.33
0.01
(0.76%)
시간외 거래: 8:05AM
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
1.33
매수가
1.33
매도가
1.35
거래량
1,033,341
1.235 일간 변동폭 1.32
1.29 52주 범위 7.795
market_cap
85.439M
전일 종가
1.30
개장가
1.29
최근 거래 시간
449
@
1.33
(formt)
마지막 거래 시간
재정 규모
US$ 1,334,748
VWAP
1.2917
평균 볼륨(3m)
727,123
발행 주식
64,240,198
배당수익률
-
주가수익률
-1.18
주당순이익(EPS)
-1.11
매출
-
순이익
-71.17M

Inozyme Pharma Inc 정보

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.inozyme.com
본부
Wilmington, Delaware, USA
설립됨
-
Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker INZY. The last closing price for Inozyme Pharma was US$1.30. Over the last year, Inozyme Pharma shares have traded in a share price range of US$ 1.29 to US$ 7.795.

Inozyme Pharma currently has 64,240,198 shares in issue. The market capitalisation of Inozyme Pharma is US$83.51 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -1.18.

INZY 최신 뉴스

추가 뉴스

Form 8-K - Current report

10 1월 2025
Edgar (US Regulatory)

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and...

10 1월 2025
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

10 12월 2024
Edgar (US Regulatory)

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

27 11월 2024
GlobeNewswire Inc.

Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

11 11월 2024
GlobeNewswire Inc.

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

09 11월 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

05 11월 2024
Edgar (US Regulatory)

Form 8-K - Current report

05 11월 2024
Edgar (US Regulatory)

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in...

05 11월 2024
GlobeNewswire Inc.

Form 8-K - Current report

25 10월 2024
Edgar (US Regulatory)
기간변동변동 %시가고가저가평균 일일 거래량VWAP
1-0.08-5.673758865251.411.4451.2912463091.34294343CS
4-1.58-54.2955326462.913.181.299021871.89351157CS
12-3.23-70.83333333334.564.64011.297271232.57416297CS
26-4.16-75.77413479055.496.241.294563643.36643956CS
52-3.22-70.76923076924.557.7951.294863874.47734001CS
156-5.31-79.96987951816.647.980.9914932384.15526284CS
260-16.6-92.582264361417.9331.64990.9913499415.04958295CS

INZY - Frequently Asked Questions (FAQ)

What is the current Inozyme Pharma share price?
The current share price of Inozyme Pharma is US$ 1.33
How many Inozyme Pharma shares are in issue?
Inozyme Pharma has 64,240,198 shares in issue
What is the market cap of Inozyme Pharma?
The market capitalisation of Inozyme Pharma is USD 83.51M
What is the 1 year trading range for Inozyme Pharma share price?
Inozyme Pharma has traded in the range of US$ 1.29 to US$ 7.795 during the past year
What is the PE ratio of Inozyme Pharma?
The price to earnings ratio of Inozyme Pharma is -1.18
What is the reporting currency for Inozyme Pharma?
Inozyme Pharma reports financial results in USD
What is the latest annual profit for Inozyme Pharma?
The latest annual profit of Inozyme Pharma is USD -71.17M
What is the registered address of Inozyme Pharma?
The registered address for Inozyme Pharma is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
What is the Inozyme Pharma website address?
The website address for Inozyme Pharma is www.inozyme.com
Which industry sector does Inozyme Pharma operate in?
Inozyme Pharma operates in the PHARMACEUTICAL PREPARATIONS sector

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
DWTXDogwood Therapeutics Inc
US$ 13.2484
(373.16%)
103.21M
DGNXDiginex Ltd
US$ 12.75
(70.00%)
9.74M
RNAZTransCode Therapeutics Inc
US$ 5.61
(60.74%)
10.9M
EVAXEvaxion Biotech AS
US$ 3.76
(57.98%)
4.02M
MCTRCTRL Group Ltd
US$ 6.77
(56.35%)
8.84M
CHSNChanson International Holding
US$ 0.83352
(-86.77%)
21.85M
ICONIcon Energy Corporation
US$ 0.5348
(-59.18%)
15.88M
JUNSJupiter Neurosciences Inc
US$ 1.50
(-58.10%)
11.08M
BACKIMAC Holdings Inc
US$ 0.78
(-42.01%)
479.52k
DXSTDecent Holding Inc
US$ 2.50
(-38.42%)
11.55M
HEPAHepion Pharmaceuticals Inc
US$ 0.203
(50.37%)
538.53M
NVDANVIDIA Corporation
US$ 147.22
(0.10%)
155.52M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.33095
(3.75%)
153.25M
RIMEAlgorhythm Holdings Inc
US$ 0.0338
(1.81%)
137.6M
RGTIRigetti Computing Inc
US$ 13.465
(-3.20%)
133.14M

INZY Discussion

게시물 보기
tj9938 tj9938 2 월 전
Taking a beating this week. 
👍️0
Monksdream Monksdream 5 월 전
INZY under $6
👍️0
AJ Freely AJ Freely 1 년 전
$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment
👍️0
Monksdream Monksdream 2 년 전
INZY new 52 week high
👍️0
INFINITI INFINITI 2 년 전
Loading
👍️0
Jess070283 Jess070283 2 년 전
Have a feeling this about to squeeze into a halt soon…..
👍️0
tj9938 tj9938 2 년 전
Great week so far. Gotta keep it movin.
👍️0
tj9938 tj9938 2 년 전
Quietest board out there
👍️0
ErnieBilco ErnieBilco 3 년 전
Grabbed a starter here today
👍️0
crudeoil24 crudeoil24 3 년 전
INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
👍️0
crudeoil24 crudeoil24 3 년 전
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
👍️0
crudeoil24 crudeoil24 3 년 전
Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY
👍️0
tw0122 tw0122 3 년 전
I like the BioXc chart looks better. Thanks for all the good insight.
👍️0
crudeoil24 crudeoil24 3 년 전
The offering is expected to close on or about April 19, 2022
👍️0
tw0122 tw0122 3 년 전
This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 3 년 전
PT > 33.00
👍️0
crudeoil24 crudeoil24 3 년 전
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
👍️0

최근 히스토리

NASDAQ
INZY
Inozyme Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유